RECRUITING

Enhancing Language Function in Aphasia

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Aphasia is an acquired impairment of language, that commonly results from damage to language areas in the brain (typically the left side of the brain). This impairment is seen in many aspects of language, including understanding, speaking, reading and writing. It is estimated that about 2 million individuals are currently living with aphasia in the United States. Further, about 200,000 Americans acquire aphasia every year (National Aphasia Association, 2020). Aphasia poses significant impact on the affected individuals and their families. Behavioral treatments that target language deficits have been shown to enhance overall communication skills and life satisfaction among individuals with aphasia. Although there is evidence that suggests that treatment is efficacious for individuals with aphasia, the extent of improvement long-term coupled with the neural patterns among those individuals are largely unknown. The current study aims to investigate the efficacy of language-based treatment and its corresponding neural patterns.

Official Title

Enhancing Language Function in Aphasia Using Behavioral Language Intervention

Quick Facts

Study Start:2022-10-30
Study Completion:2028-12-15
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05443633

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:21 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Present with speech-language impairment (aphasia) caused by stroke or dementia
  2. 2. A medical diagnosis of primary progressive aphasia (PPA) by a neurologist or physician
  3. 3. Are native speakers of English
  4. 4. Present with no contraindications for MRI
  5. 5. Have adequate (normal or corrected to normal) vision and hearing
  1. 1. Individuals diagnosed with mood, anxiety, psychotic or substance abuse disorders.
  2. 2. Individuals with highly magnetizable metallic implants, including certain dental work, may be excluded due to image quality in MRI.
  3. 3. Individuals with other neurological disorders besides the ones of interest for the study (e.g., epilepsy, Multiple Sclerosis, Parkinson's Disease)
  4. 4. Individuals with contraindications for MRI. This includes but is not limited to pacemakers, metallic cardiac pumps, valves, magnetic materials such as surgical clips, implanted electronic perfusion pumps, or any other condition that would preclude proximity to a strong magnetic field.
  5. 5. Individuals suffering from clinically significant claustrophobia
  6. 6. Severe systemic disease (e.g., renal failure)
  7. 7. Poor overall health
  8. 8. Individuals who are pregnant
  9. 9. Individuals with a history of epileptic activity in the past 12 months
  10. 10. Individuals with a personal or family history of epilepsy or other seizure disorders will not be included in the study.
  11. 11. Individuals who have had a brain surgery in the past
  12. 12. Individuals with implanted metallic skull plates or intracranial implants
  13. 13. Individuals with skin lesions or skull damage
  14. 14. Individuals who have a history of excessive use of alcohol or drugs
  15. 15. Individuals with premorbid psychiatric disease affecting communication
  16. 16. Individuals with severe non-linguistic cognitive disturbances impeding language therapy

Contacts and Locations

Study Contact

Aneta Kielar, PhD
CONTACT
15204883791
akielar@email.arizona.edu
Fatima Jebahi, MS
CONTACT
fjebahi@email.arizona.edu

Principal Investigator

Aneta Kielar, PhD
PRINCIPAL_INVESTIGATOR
University of Arizona

Study Locations (Sites)

University of Arizona
Tucson, Arizona, 85721-0071
United States

Collaborators and Investigators

Sponsor: University of Arizona

  • Aneta Kielar, PhD, PRINCIPAL_INVESTIGATOR, University of Arizona

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-10-30
Study Completion Date2028-12-15

Study Record Updates

Study Start Date2022-10-30
Study Completion Date2028-12-15

Terms related to this study

Additional Relevant MeSH Terms

  • Aphasia, Acquired
  • Language Disorders
  • Primary Progressive Aphasia
  • Stroke, Cerebrovascular